

Improving the provision of rabies post-exposure prophylaxis

Simon Cauchemez, Hervé Bourhy

▶ To cite this version:

Simon Cauchemez, Hervé Bourhy. Improving the provision of rabies post-exposure prophylaxis. The Lancet Infectious Diseases, 2019, 19 (1), pp.12-13. 10.1016/S1473-3099(18)30606-6. pasteur-04095243

HAL Id: pasteur-04095243 https://pasteur.hal.science/pasteur-04095243

Submitted on 11 May 2023 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License

- 10 Commons RJ, Simpson JA, Thriemer K, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis 2019; 19: 91–101.
- 11 Recht J, Siqueira AM, Monteiro WM, Herrera SM, Herrera S, Lacerda MVG. Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination. *Malar J* 2017; **16**: 273.
- 12 Thriemer K, Bobogare A, Ley B, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J 2018; 17: 241.
- 13 Brito MA, Peixoto HM, Almeida AC, et al. Validation of the rapid test Carestart(tm) G6PD among malaria vivax-infected subjects in the Brazilian Amazon. Rev Soc Bras Med Trop 2016; 49: 446–55.
- 14 Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of *Plasmodium vivax* malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. *Lancet* 2014; **383:** 1049–58.

Improving the provision of rabies post-exposure prophylaxis

Published Online November 21, 2018 http://dx.doi.org/10.1016/ \$1473-3099(18)30606-6 See Articles page 102 In 2015, WHO and its partners set the ambitious objective¹ to reach zero human deaths from dog-mediated rabies by 2030, after the concept of effective One Health interventions.² Mass dog vaccination is expected to be an important part of any successful strategy.^{3,4} In The Lancet Infectious Diseases, the WHO Rabies Modelling Consortium⁵ reminds us that effective and timely postexposure prophylaxis, administered to humans bitten by rabid dogs to prevent the fatal onset of rabies, is another essential tool for success.⁵ Through the analysis of a wide range of data collected in multiple countries and the use of multilayer mathematical models, the authors show that increased investment in post-exposure prophylaxis by Gavi, the Vaccine Alliance, would be extremely costeffective and could substantially reduce disease burden. The study is particularly timely because Gavi is currently reconsidering rabies vaccine investment.

Preparation of such assessment required the Consortium⁵ to overcome several major challenges. First, any assessment of post-exposure prophylaxis needs to account for a very diverse set of factors.⁶ For example, it must be based on a good understanding of dog populations, how they are structured, how they interact with humans, how they can be affected by the spread of rabies, and how that spread might be mitigated by dog vaccination.7 Furthermore, the likelihood that a bitten person will seek, obtain access to, and complete post-exposure prophylaxis treatment depends on cultural, economic, geographical, and logistical factors (eg, awareness in the population, accessibility to post-exposure prophylaxis centres, direct and indirect costs, effective stockpiling, and delivery of vaccines). Several of these factors have historically been poorly characterised and might exhibit strong spatial heterogeneities. A major strength of the analysis⁵ is that it benefited from tremendous efforts by Gavi to reduce some of these knowledge gaps by supporting rabies field studies. Consequently, the diversity of data the authors used to build their assessment is quite impressive, both in terms of data type and geographical coverage. A second achievement of the paper is that the authors developed a multidisciplinary modelling framework in which these data could be integrated in a coherent way, making it possible to generate rabies incidence dynamics in dogs and the associated human exposures under various epidemiological scenarios, while also capturing economic, behavioural, and logistical aspects.⁵

The new data and modelling framework therefore constitute an important improvement to past studies; future iterations of the work are likely to lead to additional refinements. Of course, still too many countries have little or no data available, and more field studies targeting these places are needed. Some aspects of the assessment could also be improved further. For example, in some circumstances, free provision alone might be insufficient to increase health-care seeking and accessibility. Indeed, the lack of infrastructure might make it impossible for exposed populations (especially those living in rural remote areas) to travel to clinics and access post-exposure prophylaxis,8 even if vaccines are freely available. To this regard, further investments are needed to improve the accessibility to post-exposure prophylaxis via point-of-care and decentralised integrated dog bite management centres (IDBCs).9 The geographical distribution of these IDBCs is a crucial issue in many developing countries and will require important efforts from national authorities.8 The education of populations to increase awareness and perception of the risks related to dog bite exposure and rabies is another complex issue that is starting to be addressed by stakeholders but should be promoted further.¹⁰

Hopefully, Gavi and other national and international stakeholders and donors will keep on supporting field studies so that all these aspects can be better characterised and accounted for in future assessments of rabies control strategies.

*Simon Cauchemez, Hervé Bourhy

Mathematical Modelling of Infectious Diseases Unit, CNRS UMR2000: Génomique Évolutive, Modélisation et Santé, and Center of Bioinformatics, Biostatistics and Integrative Biology, Institut Pasteur, Paris 75015, France (SC); Lyssavirus Dynamics and Host Adaptation, Institut Pasteur, Paris, France (HB) simon.cauchemez@pasteur.fr

HB reports grants from Santé Publique France during the conduct of the study and non-financial support from Humabs BioMed SA outside of the submitted work. HB also has a US provisional patent application (62/404,435; Oct 5, 2016) for phtazolinone derivatives used in the treatment and prevention of rabies; patents for antibodies that potentially neutralize rabies virus and other lyssaviruses and uses thereof (PCT/EP2014/003076; Nov 18, 2014); and for antibodies and methods for treatment of lyssavirus infection (PCT/ EP2018/078751; Oct 19, 2018). SC declares no competing interests.

Copyright \otimes 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

1 WHO. Global framework for the elimination of dog-mediated human rabies. http://www.who.int/rabies/control/Poster_Global_framework_for_ the_elimination_of_dog-mediated_human_rabies.pdf (accessed Oct 26, 2018).

- 2 Cleaveland S, Sharp J, Abela-Ridder B, et al. One Health contributions towards more effective and equitable approaches to health in low- and middle-income countries. *Philos Trans R Soc Lond B Biol Sci* 2017; 372: 20160168.
- 3 Abela-Ridder B, Knopf L, Martin S, Taylor L, Torres G, De Balogh K. 2016: the beginning of the end of rabies? Lancet Glob Health 2016; 4: e780–81.
- 4 Zinsstag J, Lechenne M, Laager M, et al. Vaccination of dogs in an African city interrupts rabies transmission and reduces human exposure. Sci Transl Med 2017; 9: eaaf6984.
- 5 WHO Rabies Modelling Consortium. The potential impact of provision of rabies postexposure prophylaxis in Gavi-eligible countries: a modelling study. Lancet Infect Dis 2018; published online Nov 21. http://dx.doi. org/10.1016/S1473-3099(18)30512-7.
- 6 Hampson K, Cleaveland S, Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis 2011; 5: e982.
- 7 Lembo T, Hampson K, Kaare MT, et al. The feasibility of canine rabies elimination in Africa: dispelling doubts with data. PLoS Negl Trop Dis 2010; 4: e626.
- 8 Tarantola A, Blanchi S, Cappelle J, et al. Rabies postexposure prophylaxis non-completion after dog bites: estimating the unseen to meet the needs of the underserved. Am J Epidemiol 2018; 187: 306–15.
- 9 Amparo ACB, Jayme SI, Roces MCR, et al. The evaluation of animal bite treatment centers in the Philippines from a patient perspective. PLoS One 2018; 13: e0200873.
- 10 Hasanov E, Zeynalova S, Geleishvili M, et al. Assessing the impact of public education on a preventable zoonotic disease: rabies. *Epidemiol Infect* 2018; 146: 227–35.

Knowledge advances and gaps on the demand side of vaccination

Vaccination is one of the most successful and costeffective interventions for preventing and controlling infectious diseases. In addition to providing direct protection for vaccinated individuals, vaccination also induces indirect protection for the community by slowing transmission of diseases.1 This effect, in turn, reduces the risk of infection among susceptible individuals and helps to prevent disease outbreaks. However, the success of vaccines depends on high levels of vaccination uptake. Supply-side factors, such as inadequate access to vaccines, remain important contributors to suboptimal vaccination uptake.² But, ensuring that individuals decide to take-up available vaccines is an additional challenge. Several studies have shown that increased numbers of individuals globally are questioning vaccines, seeking alternative vaccination schedules, and deciding to delay or refuse vaccination.3

Encouragingly, there is growing international focus on the demand side of vaccination. Various international working groups have been established in this regard one on vaccine hesitancy within WHO,⁴ one on vaccine confidence within the US National Vaccines Advisory Committee,⁵ and one on vaccine demand under the leadership of UNICEF.⁶ The 2017 Assessment Report of the Global Vaccine Action Plan also recommended that all countries develop strategies to increase acceptance and demand for vaccination.² Furthermore, academic publications examining the scope and drivers of vaccine demand have increased substantially over the past decade,³ together with the number of systematic reviews synthesising this evidence (appendix).

As an emerging focus and field of research, it is timely to reflect on the knowledge advances that have been made and the current gaps requiring attention going forward. A first major development has been the depolarisation of individuals as either anti-vaccines or pro-vaccines. Research in this area has shed light on the porous continuum of vaccine attitudes and behaviours, thus challenging previous perspectives of a simple dichotomy between vaccine acceptance and rejection. Various terms have been developed to capture this spectrum: hesitancy, confidence, trust, acceptance, demand, and uptake. However, there is See Online for appendix